MétaCan
Menu
Back to cohort
Record W3123561686 · doi:10.1093/rheumatology/keab021

Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis

2021· article· en· W3123561686 on OpenAlexaff
Nicolino Ruperto, Hermine I. Brunner, César Pacheco‐Tena, Ingrid Louw, Gabriel Vega‐Cornejo, Alberto Spindler, D. Kingsbury, Heinrike Schmeling, Arturo Borzutzky, Rubén Cuttica, C. Inman, Victor Malievskiy, Christiaan Scott, Vladimir Keltsev, Maria Teresa Terreri, Diego Oscar Viola, Ricardo Machado Xavier, María del Rocío Maldonado Velázquez, Michael Henrickson, Michael B. Clark, Karen Bensley, Xiaoming Li, Kim Hung Lo, Jocelyn H. Leu, Chyi‐Hung Hsu, Elizabeth C. Hsia, Zhenhua Xu, Alberto Martini, Daniel J. Lovell, Simone Appenzeller, Sheila Knupp Feitosa de Oliveira, Clóvis A. Silva, Deborah M. Levy, Carmen Navarrete, Yonatan Butbul Aviel, Yosef Uziel, Е.I. Alexeeva, Vladimir Chasnyk, Yury Spivakovsky, Beth S. Gottlieb, Egla Rabinovich, Andrew Zeft, Thomas A. Griffin, Deirdre De Ranieri, Ruy Carrasco

Bibliographic record

VenueLara D. Veeken · 2021
Typearticle
Languageen
FieldMedicine
TopicAutoimmune and Inflammatory Disorders Research
Canadian institutionsAlberta Children's HospitalUniversity of Calgary
FundersJanssen Research and Development
KeywordsGolimumabMedicinePharmacokineticsInternal medicineDosingRheumatoid arthritisArthritisGastroenterologyEtanercept

Abstract

fetched live from OpenAlex

OBJECTIVES: To assess efficacy, pharmacokinetics (PK) and safety of intravenous (i.v.) golimumab in patients with polyarticular-course JIA (pc-JIA). METHODS: Children aged 2 to <18 years with active pc-JIA despite MTX therapy for ≥2 months received 80 mg/m2 golimumab at weeks 0, 4, then every 8 weeks through week 52 plus MTX weekly through week 28. The primary and major secondary endpoints were PK exposure and model-predicted steady-state area under the curve (AUCss) over an 8-week dosing interval at weeks 28 and 52, respectively. JIA ACR response and safety were also assessed. RESULTS: In total, 127 children were treated with i.v. golimumab. JIA ACR 30, 50, 70, and 90 response rates were 84%, 80%, 70% and 47%, respectively, at week 28 and were maintained through week 52. Golimumab serum concentrations and AUCss were 0.40 µg/ml and 399 µg ⋅ day/ml at week 28. PK exposure was maintained at week 52. Steady-state trough golimumab concentrations and AUCss were consistent across age categories and comparable to i.v. golimumab dosed 2 mg/kg in adults with rheumatoid arthritis. Golimumab antibodies and neutralizing antibodies were detected via a highly sensitive drug-tolerant assay in 31% (39/125) and 19% (24/125) of patients, respectively. Median trough golimumab concentration was lower in antibody-positive vs antibody-negative patients. Serious infections were reported in 6% of patients, including one death due to septic shock. CONCLUSION: Body surface area-based dosing of i.v. golimumab was well tolerated and provided adequate PK exposure for clinical efficacy in paediatric patients with active pc-JIA.ClinicalTrials.gov number NCT02277444.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.268
Threshold uncertainty score0.554

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.021
GPT teacher head0.300
Teacher spread0.280 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations34
Published2021
Admission routes1
Has abstractyes

Explore more

Same venueLara D. VeekenSame topicAutoimmune and Inflammatory Disorders ResearchFrench-language works237,207